Biomarker for Cardiovascular Risk Assessment in Europe (BiomarCaRE)

At a Glance
  • Status: Active Consortium
  • Year Launched: 2011
  • Initiating Organization: European Commission Seventh Framework Programme (FP7)
  • Initiator Type: Government
  • Disease focus:
  • Location: Europe


BiomarCaRE is a collaborative research project that integrates clinical, epidemiological, and biomarker research, as well as commercial enterprises throughout Europe, North America, and Australia. The BiomarCaRE project aims to determine the additional value of multiple (new) biomarkers to improve risk estimation of cardiovascular diseases (CVD)-related events in Europe. Ultimately, our BiomarCaRE consortium will develop a "European biomarker panel" for CVD prediction including the classical risk factors and established and novel biomarkers.


Biomarkers are considered as tools to enhance cardiovascular risk estimation. However, the value of biomarkers on risk estimation beyond European risk scores, their comparative impact among different European regions, and their role in the drive toward personalized medicine remain uncertain. Based on harmonized and standardized European population cohorts, BiomarCaRE has built significant research collaboration, expertise, and infrastructure in the European Union (EU). The consortium will apply highly innovative SME-driven technologies and perform large-scale biomarker determination to assess the predictive value of existing and emerging biomarkers.

Selection of emerging biomarkers will be based on integrated cutting-edge quantitative proteomic, transcriptomic, metabolomic, and miRNomic datasets established by private and public consortium members that will be disclosed to this consortium. Existing biomarkers will be selected based on non-redundancy and their association with cardiovascular risk and phenotypes. After SME-guided development of innovative assay systems, biomarkers will be tested and validated in a step-wise fashion among European populations in primary and secondary prevention. In addition to their impact on risk prediction, their association with lifestyle determinants and cardiovascular phenotypes assessed by ultrasound and MRI technique will be evaluated.

A BiomarCaRE panel will be established, leading to improved disease prediction among different European populations. International collaborations with world-class clinical trial investigators will add data on the interaction of the BiomarCaRE panel with risk-lowering medication and lifestyle changes. The outcome of SME-driven technology development and clinical validation will undergo a medical technology assessment. The determination of cost-effectiveness will guide further clinical evaluation. These studies will reveal new methods of improved cardiovascular risk estimation and will open the path toward personalized medicine.


It is a research project co-funded under the European Unions' Seventh Framework Programme.


Sponsors & Partners

University Medical Center Hamburg-Eppendorf

National Institute for Health and Welfare

Cavadis B.V.

Universitair Medisch Centrum

Helmholtz Zentrum Muenchen

Biocrates Life Sciences AG

University Lübeck

University for Health Sciences, Medical Informatics and Technology

Medizinische Hochschule Hannover

Fleet Bioprocessing Ltd.

Biocartis SA

Research Network Services Ltd.

Universitätsmedizin der Johannes Gutenberg-Universität Mainz

University of Tromsø

Università Cattolica del Sacro Cuore

Ernst-Moritz-Arndt Universität Greifswald

University College London

The Queen's University of Belfast

Institut Pasteur de Lille

Catalan Institute of Cardiovascular Sciences

Umeå Universitet

Tartu University

Research Centre for Prevention and Health

University of Insubria

University of Dundee

Universitätsspital Basel

Universitätsklinikum Ulm

Hamilton Health Sciences Corporation

University of Sydney

Harvard Medical School, Brigham and Women's Hospital

IRCCS Istituto Neurologico Mediterraneo

Last Updated: 04/22/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.